CBD inhibited EGFR signaling in triple-negative breast cancer cells and increased a death receptor on their surface, making them significantly more susceptible to killing by natural killer immune cells.
Cancer researchers, immunotherapy scientists, and anyone following CBD's potential role in oncology research.
What the researchers found
CBD elevated FAS death receptor expression on MDA-MB-468 cells to 125% versus 83% with EGF alone, and enhanced NK-92 cell cytotoxicity, reducing cancer cell viability to 52% versus 114% with EGF alone. CBD downregulated KRAS, PI3K, and AKT.
Why it matters
Triple-negative breast cancer lacks targeted therapies. If CBD can make these cancer cells more visible to the immune system by upregulating death receptors and suppressing growth signaling, it could complement immunotherapy.
The numbers in context
FAS expression: 125.29% with CBD vs. 83.07% with EGF alone (p<0.0001). Cancer cell viability with NK cells: 52.12% with CBD vs. 113.69% with EGF alone (p<0.0001).
How the study worked
In vitro study using two TNBC cell lines (MDA-MB-468 and MDA-MB-231) treated with CBD in the presence or absence of epidermal growth factor.
What this study cannot tell us
In vitro study only; no animal or human data. CBD showed potential cytotoxicity to immune cells at certain concentrations.
How to read the evidence
Cell culture study with strong statistical significance but no in vivo validation. Results are promising but very early-stage.
When this study was published
2025 publication.
The bigger picture
Immunotherapy has transformed cancer treatment but works poorly in TNBC. Finding compounds that sensitize TNBC cells to immune attack is a major research priority.
Questions still open
- At what concentrations does CBD become toxic to NK cells?
- Would CBD enhance immunotherapy outcomes in TNBC animal models?
Common questions
What is triple-negative breast cancer?
How did CBD make cancer cells more vulnerable?
Read the original research
Cannabidiol sensitizes triple-negative breast cancer cells to NK cell-mediated killing via EGFR inhibition and FAS upregulation.
Journal of cannabis research, 7(1), 85
Citation
Garunyapakun, Perawat; Ramwarungkura, Boonyanuch; Natungnuy, Krissada; Turbpaiboon, Chairat; Yenchitsomanus, Pa-Thai; Junking, Mutita. (2025). Cannabidiol sensitizes triple-negative breast cancer cells to NK cell-mediated killing via EGFR inhibition and FAS upregulation.. Journal of cannabis research, 7(1), 85. https://doi.org/10.1186/s42238-025-00340-5
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk